Table 1. Summary of clinical characteristics of patients in the TCGA ccRCC dataset.
| TCGA | Ror2-High | Ror2-Low | P-value | |
| Sample (n) | 468 | 234 | 234 | |
| Age at Diagnosis | 61 (26–90) | 60 (26–90) | 61 (29–86) | 0.0933 |
| Gender | 1.12×10−5 | |||
| Male | 306 (65%) | 176 (75%) | 130 (55%) | |
| Female | 162 (35%) | 58 (25%) | 104 (44%) | |
| Prior Tumor (Yes) | 126 (27%) | 69 (29%) | 57 (24%) | 0.2516 |
| Clinical Stage | ||||
| Stage I | 224 (48%) | 101 (43%) | 123 (53%) | - |
| Stage II | 45 (10%) | 22 (9%) | 23 (10%) | 0.7433 |
| Stage III-IV | 199 (43%) | 111 (47%) | 88 (38%) | 0.0322 |
| Grade | ||||
| G1–G2 | 205 (44%) | 84 (36%) | 121 (52%) | - |
| G3 | 185 (40%) | 93 (40%) | 92 (39%) | 0.0678 |
| G4 | 72 (15%) | 57 (24%) | 15 (6.4%) | 2.18×10−8 |
| GX | 6 (1.3%) | 0 (0%) | 6 (2.6%) | - |
| Tumor Size (cm) | 6.57 | 6.90 | 6.24 | 0.023 |
| Staging (TNM) | ||||
| T1 | 228 (49%) | 103 (44%) | 125 (53%) | - |
| T2 | 58 (12%) | 25 (11%) | 33 (14%) | 0.8826 |
| T3–T4 | 182 (39%) | 106 (45%) | 76 (32%) | 0.0098 |
| Nodes | ||||
| Node − (N0) | 226 (48%) | 110 (47%) | 116 (50%) | - |
| Node + (N1) | 16 (3.4%) | 9 (3.7%) | 7 (2.9%) | 0.5598 |
| Node unknown (NX) | 226 (48%) | 115 (47%) | 111 (46%) | - |
| Metastasis | 1.0 | |||
| Mets − (M0) | 388 (%) | 191 (82%) | 191 (82%) | |
| Mets + (M1) | 69 (%) | 43 (18%) | 43 (18%) |